$227.8M in CY2024 Part D spend21K claims · 4K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Tolvaptan used for?
JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).
Is there a generic for Tolvaptan?
Yes. 21 ANDAs filed at FDA, 6 generic manufacturers currently shipping.
How much does my plan pay for Tolvaptan?
Across 329 Part D plans, Tolvaptan averages $21.25/unit (NADAC). Lowest available: $21.25/unit. Highest in distribution: $21.25/unit.
Is Tolvaptan on the FDA shortage list?
No. Tolvaptan is not currently on the FDA Drug Shortage Database.
6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (7 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.